Moderna, Inc. $MRNA Stock Bought by Public Sector Pension Investment Board

Public Sector Pension Investment Board raised its stake in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 57.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 159,311 shares of the company’s stock after buying an additional 58,448 shares during the quarter. Public Sector Pension Investment Board’s holdings in Moderna were worth $30,679,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. CENTRAL TRUST Co raised its stake in shares of Moderna by 36.5% in the 3rd quarter. CENTRAL TRUST Co now owns 172 shares of the company’s stock valued at $33,000 after acquiring an additional 46 shares during the period. Costello Asset Management INC lifted its holdings in shares of Moderna by 7.3% in the 3rd quarter. Costello Asset Management INC now owns 966 shares of the company’s stock worth $186,000 after acquiring an additional 66 shares during the last quarter. Physician Wealth Advisors Inc. boosted its position in shares of Moderna by 8.3% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 886 shares of the company’s stock worth $171,000 after purchasing an additional 68 shares during the period. Fortitude Family Office LLC boosted its position in shares of Moderna by 53.1% during the 3rd quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock worth $43,000 after purchasing an additional 77 shares during the period. Finally, Dogwood Wealth Management LLC increased its holdings in Moderna by 158.8% in the 3rd quarter. Dogwood Wealth Management LLC now owns 132 shares of the company’s stock valued at $25,000 after purchasing an additional 81 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Top Moderna Stories

These are some of the MRNA stories that stood out recently:

  • Neutral Sentiment: Morgan Stanley’s outlook reportedly points to potential price appreciation, while coverage of Moderna’s vaccine and oncology programs highlights growth opportunities. These prospects are balanced by uncertainty over revenue and investment needs. Article
  • Negative Sentiment: Investor concerns include forecast 2027 cash costs approaching $4 billion, alongside uncertain revenue from the company’s expanding vaccine portfolio and oncology investments. That spending outlook may intensify scrutiny of Moderna’s financial recovery and help explain weakness despite positive clinical news. Article
  • Negative Sentiment: President Stephen Hoge sold shares in transactions on November 16 and 17 under a pre-arranged Rule 10b5-1 plan. The planned sales may weigh on sentiment, although such transactions do not necessarily signal a change in his view of the company. SEC filing

Analyst Ratings Changes

A number of research analysts have commented on the company. Loop Capital set a $135.00 price target on Moderna in a research note on Wednesday, August 19th. Morgan Stanley increased their target price on Moderna from $95.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Tuesday. The Goldman Sachs Group raised their target price on Moderna from $137.00 to $195.00 and gave the company a “neutral” rating in a report on Monday, November 9th. Rothschild & Co Redburn lowered shares of Moderna from a “neutral” rating to a “sell” rating and boosted their price target for the stock from $40.00 to $81.00 in a research note on Thursday, September 3rd. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Moderna in a research report on Friday, September 25th. Six equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $120.25.

View Our Latest Stock Report on MRNA

Insider Activity

In related news, CFO James M. Mock sold 34,836 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 40,294 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the completion of the transaction, the president owned 1,525,858 shares in the company, valued at $219,921,913.54. This represents a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 275,626 shares of company stock worth $50,776,076. 10.80% of the stock is currently owned by insiders.

Moderna Price Performance

Moderna stock opened at $199.33 on Friday. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52. The company has a fifty day simple moving average of $206.87 and a 200-day simple moving average of $99.61. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $280.80.

Moderna (NASDAQ:MRNA – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. The company had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $890.25 million. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. Moderna’s quarterly revenue was up 29.2% on a year-over-year basis. During the same period last year, the firm earned ($0.51) earnings per share. Research analysts expect that Moderna, Inc. will post -5.40 EPS for the current year.

About Moderna

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Recommended Stories

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.